Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review

Drug Metabolism Reviews

Volumn 46, Issue 1, 2014, Pages 86-95

  Stout, Stephen M ^a   Cimino, Nina M ^b  

^a Wolters Kluwer Health Clinical Solutions ^*  (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

AM2201; Cannabidiol; Cannabis; Dronabinol; Drug interactions; JWH 018; JWH 073; Tetrahydrocannabinol

Indexed keywords

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; AM 2201; CANNABIDIOL; CANNABINOID; CANNABINOL; CANNABIS; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DRUG METABOLIZING ENZYME; JWH 073; KETOCONAZOLE; OMEPRAZOLE; TETRAHYDROCANNABINOL; THEOPHYLLINE; UNCLASSIFIED DRUG;

CLINICAL STUDY; COMPETITIVE INHIBITION; DRUG METABOLISM; HUMAN; IN VITRO STUDY; REVIEW; SECONDARY METABOLISM; SYSTEMATIC REVIEW;

CANNABINOL; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; METABOLIC DETOXICATION, DRUG;

EID: 84893293360     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2013.849268     Document Type: Review

References (56)

1. Al Saabi A, Allorge D, Sauvage FL, et al. (2013). Involvement of UDPglucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Drug Metab Dispos 41:568-574.
2. Ashton CH. (2001). Pharmacology and effects of cannabis: A brief review. Br J Psychiatry 178:101-106.
3. Ben Amar M. (2006). Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 105:1-25.
4. Benowitz NL, Nguyen TL, Jones RT, et al. (1980). Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 28:115-120.
5. Bland TM, Haining RL, Tracy TS, Callery PS. (2005). CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 70:1096-1103.
6. Bornheim LM, Lasker JM, Raucy JL. (1992). Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol. Drug Metab Dispos 20:241-246.
7. Chetty M, Miller R, Moodley SV. (1994). Smoking and body weight influence the clearance of chlorpromazine. Eur J Clin Pharmacol 46: 523-526.
8. Chimalakonda KC, Bratton SM, Le VH, et al. (2011). Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos 39: 1967-1976.
9. Chimalakonda KC, Seely KA, Bratton SM, et al. (2012). Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: Identification of novel cannabinoid receptor ligands. Drug Metab Dispos 40:2174-2184.
10. Coutselinis A, Michalodimitrakis M. (1981). Acetylcholinesterase activity after hashish smoking. Clin Toxicol 18:385-387.
11. Dresen S, Ferreiros N, Putz M, et al. (2010). Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 45:1186-1194.
12. ElSohly MA, Slade D. (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci 78:539-548.
13. Engels FK, de Jong FA, Sparreboom A, et al. (2007). Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 12:291-300.
14. Fattore L, Fratta W. (2011). Beyond THC: The new generation of cannabinoid designer drugs. Front Behav Neurosci 5:60.
15. Gaoni Y, Mechoulam R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647.
16. Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R. (1983). Effects of tobacco smoking and oral contraceptive use on theophylline disposition. Br J Clin Pharmacol 16:271-280.
17. Hazecamp A, Ware MA, Muller-Vahl KR, et al. (2013). The medicinal use of cannabis and cannabinoids-An international cross-sectional survey on administration forms. J Psychoactive Drugs 45:199-219.
18. Holland ML, Allen JD, Arnold JC. (2008). Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol 591:128-131.
19. Holland ML, Lau DT, Allen JD, Arnold JC. (2007). The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol 152:815-824.
20. Huestis MA. (2007). Human cannabinoid pharmacokinetics. Chem Biodivers 4:1770-1804.
21. Jiang R, Yamaori S, Takeda S, et al. (2011). Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 89:165-170.
22. Johansson E, Ohlsson A, Lindgren JE, et al. (1987). Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking. Biomed Environ Mass Spectrom 14:495-499.
23. Jusko WJ, Gardner MJ, Mangione A, et al. (1979). Factors affecting theophylline clearances: Age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci 68:1358-1366.
24. Jusko WJ, Schentag JJ, Clark JH, et al. (1978). Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin Pharmacol Ther 24:405-410.
25. Kosel BW, Aweeka FT, Benowitz NL, et al. (2002). The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16:543-550.
26. Markianos M, Stefanis C. (1982). Effects of acute cannabis use and short-term deprivation on plasma prolactin and dopamine-betahydroxylase in long-term users. Drug Alcohol Depend 9:251-255.
27. Matsunaga T, Kishi N, Higuchi S, et al. (2000). CYP3A4 is a major isoform responsible for oxidation of 7-hydroxy-Delta(8)-tetrahydrocannabinol to 7-oxo-delta(8)-tetrahydrocannabinol in human liver microsomes. Drug Metab Dispos 28:1291-1296.
28. Mazor M, Dvilansky A, Aharon M, et al. (1982). Effect of cannabinoids on the activity of monoamine oxidase in normal human platelets. Arch Int Physiol Biochim 90:15-20.
29. Mazur A, Lichti CF, Prather PL, et al. (2009). Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos 37:1496-1504.
30. Mehmedic Z, Chandra S, Slade D, et al. (2010). Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55:1209-1217.
31. Mwenifumbo JC, Sellers EM, Tyndale RF. (2007). Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking. Drug Alcohol Depend 89:24-33.
32. Nadulski T, Pragst F, Weinberg G, et al. (2005). Randomized, doubleblind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit 27:799-810.
33. Ohlsson A, Lindgren JE, Andersson S, et al. (1986). Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 13:77-83.
34. Ohlsson A, Lindgren JE, Wahlen A, et al. (1982). Single dose kinetics of deuterium labelled delta 1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Mass Spectrom 9:6-10.
35. Pacher P, Batkai S, Kunos G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462.
36. Pertwee RG. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180.
37. Pertwee RG, Howlett AC, Abood ME, et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2). Pharmacol Rev 62: 588-631.
38. Richardson TH, Jung F, Griffin KJ, et al. (1995). A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch Biochem Biophys 323:87-96.
39. Roth MD, Marques-Magallanes JA, Yuan M, et al. (2001). Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am J Respir Cell Mol Biol 24:339-344.
40. Sachse-Seeboth C, Pfeil J, Sehrt D, et al. (2009). Interindividual variation in the pharmacokinetics of delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther 85:273-276.
41. Schurr A, Rigor BM. (1984). Cannabis extract, but not delta 1- tetrahydrocannabinol, inhibits human brain and liver monoamine oxidase. Gen Pharmacol 15:171-174.
42. Shultz M. (2007). Comparing test searches in PubMed and Google Scholar. J Med Libr Assoc 95:442-445.
43. Srivastava N, Sharma RK, Singh N, Sharma B. (2012). Acetylcholinesterase from human erythrocytes membrane: A screen for evaluating the activity of some traditional plant extracts. Cell Mol Biol (Noisy-le-grand) 58:160-169.
44. Stillman RC, Wyatt RJ, Murphy DL, Rauscher FP. (1978). Low platelet monoamine oxidase activity and chronic marijuana use. Life Sci 23: 1577-1581.
45. Tournier N, Chevillard L, Megarbane B, et al. (2010). Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol 13:905-915.
46. UNODC. (2012). United Nations office on drugs and crime. World Drug Report 2012, United Nations, New York, NY.
47. Watanabe K, Matsunaga T, Kimura T, et al. (2002). Major cytochrome P450 enzymes responsible for microsomal aldehyde oxygenation of 11-oxo-Delta8- tetrahydrocannabinol and 9-anthraldehyde in human liver. Drug Metab Pharmacokinet 17:516-521.
48. Watanabe K, Matsunaga T, Yamamoto I, et al. (1995). Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 18:1138-1141.
49. Watanabe K, Yamaori S, Funahashi T, et al. (2007). Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 80: 1415-1419.
50. Yamamoto I, Narimatsu S, Shimonishi T, et al. (1984). Difference in epoxides formation and their further metabolism between delta 9- and delta 8-tetrahydrocannabinols by human liver microsomes. J Pharmacobiodyn 7:254-262.
51. Yamaori S, Ebisawa J, Okushima Y, et al. (2011a). Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 88: 730-736.
52. Yamaori S, Koeda K, Kushihara M, et al. (2012). Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab Pharmacokinet 27: 294-300.
53. Yamaori S, Kushihara M, Yamamoto I, Watanabe K. (2010). Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 79:1691-1698.
54. Yamaori S, Maeda C, Yamamoto I, Watanabe K. (2011b). Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicol 29:117-124.
55. Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. (2011c). Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 39:2049-2056.
56. Zhu HJ, Wang JS, Markowitz JS, et al. (2006). Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther 317:850-857.